Engflag

Alzer

Quick links to important sections

Alzer

Alzer_EN

Method of action: Psychoanaleptics

Treatment option: Dementia, Vascular Dementia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alzer

Quick Facts: Alzer (Memantine Hydrochloride)

Property Description
Active ingredient Memantine Hydrochloride
Form Film-coated tablet, Oral solution
Pharmacological class N-Methyl-D-aspartate (NMDA) Receptor Antagonist
Common use Management of moderate to severe dementia
Origin Synthetic compound

What is Alzer and its Active Component?

Alzer is a synthetic, prescription-only medication whose single active ingredient is Memantine Hydrochloride, a compound classified as an Anti-dementia agent. It is intended for the symptomatic management of cognitive decline in adults, and is typically administered via the oral route, most often dispensed as a film-coated tablet or solution.

The drug is broadly recognized across global medical communities, with the same active substance found in international brands such as Namenda, Axura, and Ebixa. The overall purpose of Memantine Hydrochloride is to stabilize the brain functions affected by neurodegenerative processes. The status of Alzer as a Prescription Drug (Rx) confirms that its usage requires clinical assessment and ongoing supervision.

Classification of Alzer: An NMDA Receptor Antagonist

Alzer belongs to the specific pharmacological class of N-Methyl-D-aspartate (NMDA) receptor antagonists. This classification dictates the drug's fundamental mode of operation in the central nervous system. The therapeutic intent of the medication involves the moderation of the pathologically sustained activity of the excitatory chemical messenger, glutamate. This means the drug works by selectively binding to and blocking the NMDA receptors, thereby shielding nerve cells from cumulative overstimulation.

This unique action is distinct from other classes of anti-dementia agents, representing a separate, glutamatergic approach. The general benefit is the support provided in helping patients maintain their remaining cognitive and functional abilities for a longer period in moderate to severe dementia.

Regulatory References

  1. Memantine - StatPearls - NCBI Bookshelf

What side effects are possible with Alzer?

Official Safety Profile of Alzer (Memantine Hydrochloride)

The safety profile of Alzer is established through clinical trials and post-marketing surveillance, classifying reported effects by frequency and the body system affected, according to regulatory standards from authorities such as the FDA and EMA. All factual statements are based strictly on regulatory documents, with no interpretation or advice.

Frequency-Classified Adverse Reactions

The Most Common adverse reactions observed in clinical studies (occurring in 5% or more of patients at a rate greater than placebo) typically involve the nervous and gastrointestinal systems. These include dizziness, headache, confusion, and constipation.

Common reactions reported in regulatory documentation (incidence between 1% and 10%) extend to effects such as somnolence (sleepiness), fatigue, hypertension, and vomiting. Less common reactions are also documented, such as hallucinations, which have been mainly observed in patients with more severe disease.

Serious Adverse Reactions

Post-marketing reports document rare but clinically significant adverse reactions. These include serious events across various System-Organ Classes such as acute renal failure, congestive cardiac failure, pancreatitis, and hepatitis. Severe and very rare skin disorders, such as Stevens-Johnson syndrome, have also been identified in regulatory documents.

Safety Considerations for Specific Populations

Safety limitations are defined in the labeling for specific patient populations. The medicine is contraindicated in individuals with a known hypersensitivity to memantine hydrochloride. Caution is required in patients with predisposing factors for epilepsy or a history of convulsions, as the drug has not been systematically evaluated in patients with a seizure disorder. Furthermore, special regulatory provisions exist for managing patients with severe renal impairment and caution is advised for those with severe hepatic impairment, due to potential changes in drug clearance.

Conditions that cause the urine to become more alkaline may decrease memantine elimination, which could potentially lead to drug accumulation and an increase in adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to Alzer (Memantine Hydrochloride) is documented by regulatory authorities and requires immediate professional attention. Manifestations of overdose are primarily focused on the central nervous system (CNS) and psychiatric systems.

Documented Overdose Manifestations

System Specific Signs and Symptoms
CNS / Psychiatric Somnolence, dizziness, stupor, gait disturbance, confusion, agitation, hallucinations, muscle rigidity, and lethargy.
Cardiovascular Bradycardia (slow heart rate).

Required Emergency Actions

The official guidance mandates that individuals seek immediate medical attention for any suspected overdose event. Severe overdose may lead to life-threatening outcomes, including seizures, coma, and loss of consciousness, which necessitates immediately contacting emergency services. The severity and duration of these manifestations may be prolonged in patients with impaired renal function.

Management and Monitoring

Management is defined as symptomatic and supportive treatment, as no specific antidote is known for Memantine Hydrochloride. Close hospital monitoring is required, including the assessment of vital signs and continuous cardiac rhythm monitoring. Procedures such as gastric lavage or activated charcoal may be considered depending on the regulatory context and time since ingestion.

Therapeutic Uses of Alzer

Alzer (Memantine Hydrochloride) is commonly used for the symptomatic management of moderate to severe dementia, primarily of the Alzheimer's type. The medicine is applied in clinical settings when symptoms have progressed to significantly interfere with the patient’s memory, behaviour, and functional independence.

The medication is relevant for easing symptoms related to cognitive decline, functional impairment, and neuropsychiatric disturbances often present in later-stage dementia. This comprehensive symptomatic approach is often applied in scenarios where additional management of discomfort is required, playing a role in supporting the patient during difficult episodes.

“Alzer may assist with maintaining functional and cognitive stability, supporting the patient during difficult episodes by easing distress.”

Alzer helps address symptom clusters that interfere with daily functioning, assisting with maintaining functional stability and providing supportive relief when symptoms interfere with routine activities. The medication may assist with maintaining cognitive stability, which helps patients cope more steadily with these difficult mental challenges over time, and contributes to easing the overall symptom load by managing agitation and aggression.

Quick Fact: Symptom Support
Primary Focus Managing symptoms in moderate to severe Alzheimer's disease
Symptoms Addressed (Cognitive) Helps with memory loss and confusion
Behavioral Role Applied to ease agitation and aggression

Regulatory References

  1. European Medicines Agency

Eligibility and Restrictions for Use

Alzer is a medication (which contains donepezil hydrochloride) primarily used to treat the symptoms of dementia of the Alzheimer’s type, including mild, moderate, and severe stages. It works by affecting chemical messengers in the brain and is typically prescribed to adults aged 18 and older.

However, Alzer is not suitable for everyone. It is contraindicated in patients with a known hypersensitivity or allergic reaction to donepezil, piperidine derivatives, or any of the drug's inactive ingredients.

Use with Caution

Careful consideration and close monitoring are necessary for individuals with certain medical conditions, as Alzer can potentially exacerbate them due to its pharmacological effects. These include:

  • Heart Conditions: Patients with a history of heart rhythm disorders (such as sick sinus syndrome), a slow heartbeat (bradycardia), or other cardiac conduction abnormalities.
  • Gastrointestinal Issues: Those with a history of peptic ulcers or gastrointestinal bleeding. The risk of developing ulcers is higher, especially if a patient is also taking Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
  • Respiratory Illnesses: Individuals with asthma or other chronic obstructive pulmonary diseases (COPD).
  • Other Conditions: A history of seizures or conditions that can cause bladder outflow obstruction. Caution is also advised in patients with low body weight or those undergoing surgical procedures requiring anesthesia, as Alzer may interact with certain muscle relaxants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of this medicine is structured around two key areas: its metabolism by liver enzymes and its primary action as a cholinesterase inhibitor.

Pharmacokinetic Interactions (Metabolism)

Interacting Substance Category Regulatory Statement
Inhibitors of CYP3A4 and/or CYP2D6 Co-administration with strong inhibitors, such as Ketoconazole (CYP3A4) or Quinidine (CYP2D6), is documented to increase the drug's plasma concentration ( AUC and C max), necessitating monitoring.
Inducers of CYP3A4 and/or CYP2D6 Co-administration with enzyme inducers, including Phenytoin, Carbamazepine, or Rifampicin, is documented to decrease the drug's plasma concentrations substantially, potentially reducing its effect.

Pharmacodynamic Interactions

Interacting Substance Category Regulatory Statement
Anticholinergic Agents These medications may oppose the drug’s effects; concomitant use is officially documented to be avoided due to the potential for mutual antagonism.
Other Cholinergic Agents Concurrent use with other cholinesterase inhibitors or cholinergic agonists is documented to require caution due to the risk of additive or synergistic effects on the cholinergic system.
Neuromuscular Blocking Agents The drug is documented to likely exaggerate the muscle relaxation produced by Succinylcholine-type agents during anesthesia, which must be carefully considered in the pre-operative setting.

Mechanism of Action

Selective Targeting of Excitatory NMDA Receptors

Alzer's active component acts as an uncompetitive, low-affinity antagonist of the N-methyl-D-aspartate (NMDA) receptor, a key component of the brain's glutamatergic system. By binding to the receptor's ion channel only when it is open, the mechanism ensures the drug selectively engages pathways that are chronically overactive. This targeted action is used to modulate the flow of positive ions through the channel, initiating a modulatory physiological consequence.

Preventing Neuronal Excitotoxicity

The critical consequence of NMDA receptor overstimulation is the excessive influx of calcium ions ( Ca^2+) into the nerve cell, a process called excitotoxicity that leads to cellular damage. Alzer's mechanism is specifically designed to suppress this pathological Ca^2+ surge, thereby dampening the destructive molecular cascade. This intervention results in the regulation of overactive processes and reduces cellular stress within the central nervous system.

Preserving Essential Synaptic Signaling

A unique feature of the mechanism is its fast off-rate from the receptor, which allows the drug to quickly vacate the channel during the brief, high-intensity signals required for normal synaptic plasticity. This mechanism contributes to a more regulated state within the targeted pathways by suppressing pathological "noise" while preserving the necessary physiological "signal," resulting in the maintenance of the integrity of residual synaptic activity.

Dosage and Administration Information

Administration Scope and Dosing Rules

Alzer (Memantine Hydrochloride) is administered exclusively by the oral route in the form of immediate-release (IR) tablets, an oral solution, or extended-release (ER) capsules. All forms may be taken with or without food. The regimen is long-term and relies on a required gradual titration schedule to establish the full maintenance dose over several weeks, with a minimum interval of one week between all dose increases.

Dosing Regimen Frequency Maximum Daily Dose
Immediate-Release Two divided doses 20 mg/day
Extended-Release Once daily 28 mg/day

Preparation and Administration Specifics

The ER capsule must be swallowed whole; it must not be crushed or chewed. Alternatively, the capsule contents may be opened and sprinkled onto a small amount of applesauce and consumed immediately, with no dividing of the dose. The oral solution must not be mixed with any other liquid. If a single dose is missed, it must not be doubled; the next scheduled dose should be taken as planned. If treatment is interrupted for several days, it is recommended to resume at a lower dose and re-titrate.

Population-Specific Instructions

A specific maximum dose is established for patients with diminished kidney function. For severe renal impairment (creatinine clearance 5–29 mL/min), the maximum daily dose must be reduced to 10 mg/day for the IR form or 14 mg for the ER form. The medicine is not recommended for use in the pediatric population (under 18 years).

Recent Clinical Evidence

Alzer: Recent Clinical Evidence

Evidence for use in Major Depressive Disorder (MDD)

Research for Major Depressive Disorder largely includes short-term randomized controlled trials (RCTs), typically lasting around six to eight weeks. These studies were used in research exploring how symptoms change over time and commonly studies monitored outcomes related to symptom intensity or variability using standardized rating scales in adult populations. Findings describe patterns observed in these studies, which generally reported measurements of changes in depression symptom scale scores compared to a control or placebo group during the defined period. Long-term outcomes are not fully established. Follow-up durations were limited in most trials, and evidence quality varies across studies.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research examining Generalized Anxiety Disorder largely included short-term outcomes, mainly through RCTs applied in studies examining patient-reported experiences. These studies explored symptom changes over brief, defined time intervals, with primary outcomes focused on how symptoms are measured using established anxiety severity rating scales. Data show patterns related to reported measurements of changes in anxiety scale scores over the short-term treatment period. Evidence suggests changes were measured during the study period, which, in some instances, was associated with the intervention when compared to placebo. Comparative evidence is lacking to fully understand how these short-term findings relate to other established treatment options.

What is still uncertain about Alzer

The evidence landscape contributes to understanding symptom patterns but indicates several areas where certainty remains low. Comparative evidence is lacking to contrast Alzer's observed patterns with other available treatment options for MDD and GAD. Specifically, there is limited information for long-term outcomes, and data on long-term outcomes remain partial. Research does not determine whether an individual will respond similarly. Subgroup findings are uncertain, and data for certain groups, such as pediatric patients or older adults, remain insufficient.

Key Studies & References

  1. Selective Serotonin Reuptake Inhibitors - StatPearls (General Review of Indications and Mechanism Context)
  2. Placebo-controlled randomized clinical trials of antidepressants for major depressive disorder: Analysis of ClinicalTrials.gov, 2008-2022
  3. NICE Guideline [NG222]: Depression in adults: treatment and management

How should Alzer be stored and disposed of?

The official requirements for storing and disposing of Alzer must be followed to maintain its stability and effectiveness.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Do not store above 30 C.
Protection Keep in the original container to protect from moisture and light. Do not refrigerate or freeze the product.
Child Safety Keep Alzer out of the sight and reach of children in a child-resistant closure.

Stability and Disposal

Requirement Official Regulatory Statement
Stability The product must be used by the labeled expiration date. Discard unused medicine after a specified time (e.g., 6 months) following initial container opening.
Disposal Do not dispose of Alzer by flushing it down a toilet or pouring it into a drain. Unused or expired medication must be disposed of through an authorized drug take-back or collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTurkey

Equivalent of Alzer found in:

A-Z Index: